Reproductive · PANCE / PANRE

Preeclampsia and Eclampsia

New-onset hypertension + proteinuria or end-organ dysfunction after 20 weeks gestation; eclampsia adds seizures.

Also known as: preeclampsia, eclampsia, HELLP syndrome, gestational hypertension, hypertensive disorders of pregnancy

Overview

Hypertensive disorder of pregnancy characterized by new-onset hypertension (≥140/90 on two occasions ≥4 hours apart) after 20 weeks gestation with either proteinuria (≥300 mg/24 h, protein:creatinine ratio ≥0.3, or dipstick 2+) or new-onset end-organ dysfunction. Severe features warrant urgent management. Eclampsia is preeclampsia with new-onset tonic-clonic seizures. HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets) is a severe variant.

Epidemiology

Affects ~5-8% of pregnancies in the US; major contributor to maternal and perinatal morbidity and mortality. Higher rates in nulliparous, advanced maternal age, multifetal, and historically marginalized populations.

Try two board-style Preeclampsia and Eclampsia questions

Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.

Question 1ReproductiveMedium
A 32-year-old woman at 36 weeks gestation has a blood pressure of 156/102 mm Hg confirmed on two readings 4 hours apart, 3+ proteinuria on dipstick, a serum creatinine of 1.3 mg/dL, and a new persistent headache. Which of the following is the most likely diagnosis?
  • AChronic hypertension
  • BGestational hypertension
  • CPreeclampsia with severe features
  • DHELLP (hemolysis, elevated liver enzymes, low platelets) syndrome
Reveal answer & full explanation
Correct answer: C — Preeclampsia with severe features
  • AChronic hypertension
  • BGestational hypertension
  • CPreeclampsia with severe features
  • DHELLP (hemolysis, elevated liver enzymes, low platelets) syndrome

Why preeclampsia with severe features is correct

  • After 20 weeks gestation this patient has new hypertension (156/102 mm Hg on two readings) plus 3+ proteinuria, establishing preeclampsia.
  • Severe features are present: a serum creatinine of 1.3 mg/dL indicates renal insufficiency (>1.1 mg/dL) and the new persistent headache is a cerebral symptom — either one alone upgrades the diagnosis to severe features. Note that 156/102 mm Hg is below the severe-range threshold (>=160/110), so the severity here derives from the renal insufficiency and headache, not the blood pressure itself.
  • Management is magnesium sulfate for seizure prophylaxis, IV labetalol or hydralazine for sustained severe-range pressures, and delivery as the definitive treatment.

Why the others are wrong

  • Chronic hypertension — defined by elevated blood pressure before 20 weeks or pre-pregnancy; it does not produce new proteinuria, renal insufficiency, or headache at 36 weeks. Sets the anchoring trap of fixating on the blood pressure alone.
  • Gestational hypertension — new hypertension after 20 weeks but WITHOUT proteinuria or end-organ involvement; the 3+ proteinuria and creatinine of 1.3 mg/dL exclude it. Sets the premature-closure trap of stopping at the mildest diagnosis.
  • HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome — requires laboratory evidence of hemolysis, transaminitis, and thrombocytopenia, none of which is reported here. Sets the buzzword trap of jumping to the most dramatic preeclampsia variant without its defining labs.
Question 2ReproductiveEasy
A 24-year-old at 38 weeks has BP 156/104 on two readings, 2+ proteinuria, and a severe persistent headache for 3 hours. Platelet count is 140K. Which of the following is the most appropriate management?
  • AAntenatal corticosteroids with delivery deferred 48 hours
  • BOral labetalol with inpatient observation and daily labs
  • CIV magnesium, IV antihypertensives, and prompt delivery
  • DExpectant management with close fetal monitoring
Reveal answer & full explanation
Correct answer: C — IV magnesium, IV antihypertensives, and prompt delivery
  • AAntenatal corticosteroids with delivery deferred 48 hours
  • BOral labetalol with inpatient observation and daily labs
  • CIV magnesium, IV antihypertensives, and prompt delivery
  • DExpectant management with close fetal monitoring

Why IV magnesium, IV antihypertensives, and prompt delivery is correct

  • This is preeclampsia with severe features. Although the BP (156/104) is below the severe range (≥160/110), the new-onset severe persistent headache is a cerebral severe feature that establishes the diagnosis.
  • IV magnesium sulfate (MgSO4) is given for seizure prophylaxis: 4 g loading dose then 1–2 g/hour maintenance.
  • IV antihypertensives (labetalol or hydralazine) are given if BP reaches severe range (≥160/110); here delivery and magnesium are the priority, with antihypertensives ready if BP escalates.
  • Delivery is the definitive treatment; at 38 weeks with severe features, proceed to delivery without delay.
  • Severe headache represents CNS involvement and mandates delivery regardless of gestational age.

Why the others are wrong

  • A) Antenatal corticosteroids with delivery deferred 48 hours — Corticosteroids to accelerate fetal lung maturity are only needed if <34 weeks; at 38 weeks fetal lung maturity is established and delaying delivery with severe features is dangerous.
  • B) Oral labetalol with inpatient observation and daily labs — Admission and oral blood pressure control omit the two interventions this diagnosis requires: magnesium sulfate for seizure prophylaxis and delivery, which is the only definitive treatment at 38 weeks with a severe feature.
  • D) Expectant management with close fetal monitoring — Expectant management may be considered for preeclampsia without severe features between 34–37 weeks, but is not appropriate with severe features at 38 weeks.
🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Preeclampsia and Eclampsia outline — plus all 514 diagnoses, 6,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Free to start · No credit card · Cancel anytime

Risk factors

  • Nulliparity
  • Prior preeclampsia
  • Chronic hypertension, pregestational diabetes, CKD
  • Antiphospholipid syndrome, autoimmune disease
  • Multifetal gestation
  • Obesity
  • Advanced maternal age (>35)
  • Family history of preeclampsia
  • IVF / oocyte donation
  • Hydatidiform mole (can cause preeclampsia <20 weeks)

Pathophysiology

Abnormal placentation with incomplete trophoblast invasion of maternal spiral arteries → placental ischemia → release of antiangiogenic factors (sFlt-1, soluble endoglin) and inflammatory mediators → systemic endothelial dysfunction → vasoconstriction, increased vascular permeability, end-organ ischemia, and activation of coagulation cascade.

Clinical presentation

Symptoms

  • Often asymptomatic — detected on routine BP and urine checks
  • Severe headache, visual disturbances (scotoma, blurred vision)
  • Right upper quadrant or epigastric pain (hepatic capsule stretching)
  • Sudden weight gain, generalized edema (especially face and hands)
  • Nausea, vomiting
  • Seizures (eclampsia)
  • Dyspnea (pulmonary edema)

Signs / physical exam

  • Hypertension (≥140/90 confirmed)
  • Severe HTN ≥160/110
  • Hyperreflexia, clonus
  • Epigastric tenderness, RUQ tenderness
  • Pulmonary edema (crackles, hypoxia)
  • Altered mental status, focal neurologic findings
  • Edema is not a diagnostic criterion but commonly present

Differential diagnosis

  • Chronic hypertension — Pre-pregnancy HTN or detected <20 weeks; persists postpartum
  • Gestational hypertension — New HTN after 20 weeks WITHOUT proteinuria or end-organ dysfunction (some progress to preeclampsia)
  • Acute fatty liver of pregnancy — Hypoglycemia, marked LFT elevation, coagulopathy; can mimic HELLP
  • Thrombotic thrombocytopenic purpura (TTP) — Pentad: MAHA, thrombocytopenia, fever, renal, neurologic; ADAMTS13 activity
  • Hemolytic uremic syndrome (atypical aHUS) — MAHA, thrombocytopenia, AKI; complement dysregulation
  • Primary seizure disorder — History of epilepsy; eclampsia is presumed in any seizure during pregnancy until proven otherwise
  • Lupus flare — Multisystem involvement, low complement, anti-dsDNA

Diagnostic workup

Diagnostic criteria

Preeclampsia: BP ≥140/90 on two occasions ≥4 hours apart after 20 weeks PLUS either proteinuria (≥300 mg/24h, P:Cr ≥0.3, or dipstick 2+) OR one of: platelets <100,000, creatinine >1.1 or doubling, AST/ALT >2x ULN, pulmonary edema, or new-onset cerebral/visual symptoms. Severe features: BP ≥160/110, platelets <100,000, AST/ALT >2x ULN, creatinine >1.1 or doubling, pulmonary edema, cerebral/visual symptoms, severe persistent RUQ/epigastric pain. (Proteinuria is NOT required for severe features classification, and its absence does not exclude diagnosis if end-organ dysfunction is present.)

Labs

  • Urinalysis with protein quantitation (24-h urine protein, P:Cr ratio, or dipstick)
  • CBC (thrombocytopenia in HELLP, hemoconcentration)
  • BMP (elevated creatinine in severe disease)
  • LFTs (AST/ALT >2x ULN = severe feature; HELLP)
  • LDH and peripheral smear (hemolysis: elevated LDH, schistocytes)
  • Uric acid (rises early in preeclampsia)
  • Coagulation studies if HELLP or severe
  • sFlt-1/PlGF ratio (in some centers — prognostic, ratio <38 has high NPV)

Imaging

  • Fetal: ultrasound for growth, amniotic fluid, biophysical profile, umbilical artery Doppler
  • Maternal: CT/MRI head if focal neurologic findings, atypical seizures, or refractory disease
  • Echocardiogram if cardiac dysfunction suspected

Diagnostic algorithm

CriterionPreeclampsia (without severe)Preeclampsia with Severe Features
BP≥140/90 on 2 occasions ≥4 h apart≥160/110 (severe range, can be confirmed in shorter interval)
Proteinuria≥300 mg/24 h, P:Cr ≥0.3, or dipstick 2+Not required for severe diagnosis
PlateletsNormal<100,000
LFTsNormalAST or ALT >2x ULN, or severe RUQ/epigastric pain
RenalNormalCreatinine >1.1 or doubled from baseline
PulmonaryNormalPulmonary edema
NeurologicNormalNew-onset cerebral or visual symptoms
ManagementDelivery at 37 weeks; close monitoringDelivery; magnesium sulfate; antihypertensives; <34 wk individualized
Diagnostic criteria for preeclampsia and severe features (ACOG).

Treatment

First-line

  • Definitive treatment is delivery of the placenta — timing depends on gestational age, severity, and fetal status
  • Preeclampsia without severe features ≥37 weeks: delivery
  • Preeclampsia with severe features ≥34 weeks: delivery; <34 weeks individualized with antenatal corticosteroids and close monitoring at tertiary center
  • Severe HTN (≥160/110): rapid BP control with IV labetalol, IV hydralazine, OR oral immediate-release nifedipine (initial agents)
  • Magnesium sulfate for seizure prophylaxis — preeclampsia with severe features, eclampsia, or HELLP: loading 4-6 g IV over 15-20 min, then 1-2 g/h infusion; continue 24 h postpartum
  • Antihypertensive maintenance for chronic management: labetalol, nifedipine ER, methyldopa (less commonly used now)
  • Avoid ACEi/ARB and atenolol in pregnancy

Eclampsia

  • ABCs, left lateral decubitus position, oxygen, IV access
  • Magnesium sulfate IV — first-line for treatment AND prevention of recurrent seizures (4-6 g loading then 1-2 g/h; redose 2-4 g if seizure recurs)
  • Rapid BP control
  • Delivery once stabilized (regardless of gestational age)
  • Continue magnesium ≥24 h postpartum
  • Recurrent seizures despite magnesium: lorazepam or sodium amytal; consider CT head

HELLP syndrome

  • Magnesium sulfate for seizure prophylaxis
  • Antihypertensive control
  • Delivery once maternal stabilized (regardless of gestational age unless <34 wk and patient stable for corticosteroid window)
  • Antenatal corticosteroids if <34 weeks
  • Platelet transfusion if <20,000 or <40,000 with bleeding or planned C-section
  • Magnesium sulfate × 24-48 h postpartum

Prevention

  • Low-dose aspirin 81-162 mg daily starting at 12-16 weeks for women at high risk (prior preeclampsia, chronic HTN, diabetes, CKD, autoimmune disease, multifetal) or with ≥2 moderate risk factors
  • Calcium supplementation in low-intake populations
  • Weight management before pregnancy

Complications

  • Maternal: stroke (especially with uncontrolled severe HTN), pulmonary edema, acute kidney injury, hepatic rupture (HELLP), DIC, placental abruption, eclamptic seizures, death
  • Fetal: IUGR, oligohydramnios, prematurity, stillbirth, placental abruption
  • Long-term maternal: doubled lifetime cardiovascular disease risk, recurrent preeclampsia in future pregnancies
  • Postpartum: continued or new-onset preeclampsia/eclampsia possible up to 6 weeks postpartum

PANCE pearls

  • Magnesium sulfate is the drug of choice for seizure prevention and treatment in preeclampsia/eclampsia — NOT benzodiazepines or phenytoin first-line.
  • Monitor magnesium toxicity: loss of deep tendon reflexes (first), respiratory depression, cardiac arrest; treat with calcium gluconate 1 g IV.
  • Postpartum preeclampsia/eclampsia is well-recognized and can occur up to 6 weeks after delivery — counsel patients about warning symptoms.
  • Avoid ACE inhibitors and ARBs in pregnancy (renal anomalies, oligohydramnios, fetal demise) — switch to labetalol, nifedipine, or methyldopa.
  • Low-dose aspirin starting at 12-16 weeks reduces preeclampsia incidence in high-risk women by ~24% (USPSTF Grade A).
  • Preeclampsia is a marker for future cardiovascular disease — counsel about long-term risk modification.
  • Treat severe HTN within 30-60 minutes of confirmation to reduce stroke risk.

References

  • ACOG PB 222 — ACOG Practice Bulletin No. 222: Gestational Hypertension and Preeclampsia
  • ACOG CO 743 — ACOG Committee Opinion 743: Low-Dose Aspirin Use During Pregnancy
  • USPSTF 2021 — Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: USPSTF Recommendation Statement (JAMA 2021)
  • Magpie Trial — Magnesium Sulfate vs Placebo for Women with Preeclampsia (Magpie Trial Collaborative, Lancet 2002)

Practice Reproductive questions on FirstPassPA

Turn this outline into retention. 6,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Answer the 2 free questions above → Get today's free question →

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.